Melanoma-associated antigen 10 peptide presented by Human leukocyte antigen A*02:06 (MAGE-A10/HLA-A*02:06)

MAGE-A10 (Melanoma-associated antigen 10) is a member of the MAGE-A family of cancer-testis antigens (CTAs). Under physiological conditions, its expression is restricted to the immune-privileged germ cells of the testis and placenta, but it is aberrantly expressed in a variety of solid tumors, including lung, bladder, and head and neck cancers (UniProt P43363). The MAGE-A10 peptide presented by the Human Leukocyte Antigen (HLA) allele A*02:06 forms a specific peptide-MHC (pMHC) complex on the surface of malignant cells. This complex serves as a highly specific target for immunotherapy, as the intracellular nature of MAGE-A10 makes it inaccessible to traditional antibody therapies but visible to T-cell receptors (TCRs). Therapeutic strategies targeting this complex primarily involve adoptive cell transfer using T cells engineered with a high-affinity TCR (TCR-T therapy), such as ADP-A2M10. HLA-A*02:06 is a common variant of the HLA-A2 serotype, particularly prevalent in East Asian populations, and its inclusion in clinical targeting expands the treatable patient population beyond those carrying the more common HLA-A*02:01 allele. Because MAGE-A10 is not expressed in healthy somatic tissues, drugs targeting this pMHC complex are designed to selectively eliminate tumor cells while minimizing damage to normal organs. However, clinical development requires rigorous screening for potential cross-reactivity with other proteins to avoid severe adverse events.

Other names

MAGEA10-HLA-A*02:06MAGE-A10 peptide-MHC complexHLA-A*02:06-restricted MAGE-A10Cancer/testis antigen 1.10

T-cell receptor (TCR) engineered T-cell therapy designed to recognize and bind the specific MAGE-A10 peptide presented by HLA-A*02:01 or HLA-A*02:06 alleles, leading to T-cell mediated lysis of the tumor cell.